MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 1, 2004--C. R. Bard, Inc.
(NYSE-BCR) today announced that it has completed the previously
announced transaction to sell certain assets of its Endoscopic
Technologies division to Conmed Corporation (NASDAQ-CNMD), for $80
million, subject to post-closing adjustment.
C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
This press release may contain forward-looking statements, the
accuracy of which is necessarily subject to risks and uncertainties.
Please refer to our June 30, 2004 10-Q for a statement with regard to
forward-looking statements, including disclosure of the factors that
could cause actual results to differ materially from those expressed
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908-277-8413
Holly P. Glass, 703-754-2848
SOURCE: C. R. Bard, Inc.